CDK4 and breast carcinoma: At the same time, studies have found that CDK4/6 inhibitors inhibit the proliferation of Treg cells by inducing the secretion of IL‐29, IL‐28a and IL‐28b from senescent breast cancer cells, overcoming tumour immune evasion and enhancing anti‐tumour immunity.99